Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Topical Corticosteroids: Results from Two Randomised Monotherapy Phase 3 Trials.
Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic...
Read More